Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208

NCT02578082 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT02578082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02578082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208
Lead sponsor
Mylan Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
May 31, 2016
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment